Omomyc was initially used as a MYC inhibitor within cells and later demonstrated efficacy against transformed cells while minimally affecting normal cell proliferation.279–281 Interestingly, the theorized application of Omomyc was originally deemed implausible due to the difficulty of achieving a deliverable expression of Omomyc peptides and lack of translation to in vivo models.278,282 Subsequent testing in mouse models revealed Omomyc to possess efficacy and a remarkable therapeutic window across various tumor types, regardless of their origin or driving mutations. Here, MYC is linked to neoplasm.